Home Tools
Log in
Cart

Phospholipase

A phospholipase is an enzyme that hydrolyzes phospholipids[1] into fatty acids and other lipophilic substances. There are four major classes, termed A, B, C and D, which are distinguished by the type of reaction which they catalyze.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T38001 LEI-401 2393840-15-6 99.79%
LEI-401
LEI-401 is a selective and potent NAPE-PLD inhibitor that crosses the blood-brain barrier (IC50: 27 nM).LEI-401 reduces the level of n-acylethanolamines (NAEs) i...
T14829 Bromoenol lactone 88070-98-8 98%
Bromoenol lactone
Bromoenol lactone is a suicide-based irreversible, selective, potent inhibitor of calcium-independent phospholipase A2 (iPLA2β; IC50: ~7 μM). It inhibits antigen...
T11873 Lp-PLA2-IN-2 2071636-15-0 98%
Lp-PLA2-IN-2
Lp-PLA2-IN-2 is a selective and potent lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 0f 120 nM for recombinant human Lp-PLA2.
T78141 LFHP-1c 2102347-47-5 98%
LFHP-1c
LFHP-1c, a neuroprotective PGAM5 inhibitor, demonstrates efficacy in preserving blood-brain barrier integrity following ischemic stroke. It achieves this by bind...
T78161 VU0364739 1244639-78-8 98%
VU0364739
VU0364739, a selective phospholipase D2 (PLD2) inhibitor with an IC50 of 22 nM, effectively reduces cancer cell proliferation [1].
T79010 Lp-PLA2-IN-12 2637485-14-2 98%
Lp-PLA2-IN-12
Lp-PLA2-IN-12 (compound 19), an Lp-PLA2 inhibitor, is utilized in researching neurodegenerative diseases including Alzheimer's disease (AD), glaucoma, age-relate...
T79073 Lp-PLA2-IN-13 2756855-62-4 98%
Lp-PLA2-IN-13
Lp-PLA2-IN-13 (compound 15), a potent Lp-PLA2 inhibitor, holds potential for research in neurodegenerative-related diseases [1].
T79074 Lp-PLA2-IN-14 2756855-66-8 98%
Lp-PLA2-IN-14
Lp-PLA2-IN-14 (Compound 19), an inhibitor of rhLp-PLA2, exhibits a potent inhibitory effect with a pIC50 value of 8.4. This compound is applicable in research pe...
T79075 Lp-PLA2-IN-15 1865796-11-7 98%
Lp-PLA2-IN-15
Lp-PLA2-IN-15 (example 2) is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with potential application in Alzheimer's disease research [1].
T79076 Lp-PLA2-IN-16 1865780-73-9 98%
Lp-PLA2-IN-16
Lp-PLA2-IN-16 (Example 1) is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with potential applications in Alzheimer's disease research [1].
T79321 NSMase2-IN-1 98%
nSMase2-IN-1
nSMase2-IN-1 is an orally active inhibitor of Neutral sphingomyelinase 2 (nSMase2) with a potent IC50 value of 0.13 ± 0.06 μM. It demonstrates metabolic stabilit...
T82421 FAAH/cPLA2α-IN-1 1696401-38-3 98%
FAAH/cPLA2α-IN-1
FAAH/cPLA2α-IN-1 is a compound that simultaneously inhibits both FAAH and cPLA2α, demonstrating potent activity with half-maximal inhibitory concentrations (IC50...
T83225 A4333 98%
A4333
A4333, a biotinylated derivative of A3373, selectively inhibits Phospholipase D1 (PLD1) while sparing PLD2. It is noted for its significant role in antitumor act...
T83226 A3373 98%
A3373
A3373 is a novel inhibitor targeting both Phospholipase D1 (PLD1) and Phospholipase D2 (PLD2), demonstrating half maximal inhibitory concentrations (IC50) of 325...
T11835 LCL521 1226851-11-1 98%
LCL521
LCL521 inhibits lysosomal acid sphingomyelinase (ASMase).LCL521 is an acid ceramidase (ACDase) inhibitor.
TN3139 5α-Hydroxycostic acid 132185-83-2 98%
5α-Hydroxycostic acid
5alpha-Hydroxycostic acid possesses anti-angiogenic ability by interfering the VEGF- and Ang2-related pathways, and it may be a good drug candidate.
T74778 ASM-IN-1 2913151-46-7 98%
ASM-IN-1
ASM-IN-1 is a potent, orally active inhibitor of acid sphingomyelinase (ASM) with an IC50 of 1.5 µM, demonstrating antiatherosclerotic and anti-inflammatory acti...
T9001 Desketoraloxifene 216570-81-9 98%
Desketoraloxifene
Desketoraloxifene is a selective estrogen receptor modulator, inhibiting mammalian PLD (PLD1 and PLD2).
TN4247 Ikshusterol 3-O-glucoside 112137-81-2 98%
Ikshusterol 3-O-glucoside
Ikshusterol 3-O-glucoside has a potent snake-venom neutralizing capacity and it might be a potential molecule for the therapeutic treatment for snakebites.
T8968 ML299 1426916-00-8 98%
ML299
ML299 (VU0463568) is a dual PLD1/2 inhibitor (PLD1 and PLD2, IC50 of 6 nM, 20 nM, respectively).
LEI-401
T38001
LEI-401 is a selective and potent NAPE-PLD inhibitor that crosses the blood-brain barrier (IC50: 27 nM).LEI-401 reduces the level of n-acylethanolamines (NAEs) i...
Bromoenol lactone
T14829
Bromoenol lactone is a suicide-based irreversible, selective, potent inhibitor of calcium-independent phospholipase A2 (iPLA2β; IC50: ~7 μM). It inhibits antigen...
Lp-PLA2-IN-2
T11873
Lp-PLA2-IN-2 is a selective and potent lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 0f 120 nM for recombinant human Lp-PLA2.
LFHP-1c
T78141
LFHP-1c, a neuroprotective PGAM5 inhibitor, demonstrates efficacy in preserving blood-brain barrier integrity following ischemic stroke. It achieves this by bind...
VU0364739
T78161
VU0364739, a selective phospholipase D2 (PLD2) inhibitor with an IC50 of 22 nM, effectively reduces cancer cell proliferation [1].
Lp-PLA2-IN-12
T79010
Lp-PLA2-IN-12 (compound 19), an Lp-PLA2 inhibitor, is utilized in researching neurodegenerative diseases including Alzheimer's disease (AD), glaucoma, age-relate...
Lp-PLA2-IN-13
T79073
Lp-PLA2-IN-13 (compound 15), a potent Lp-PLA2 inhibitor, holds potential for research in neurodegenerative-related diseases [1].
Lp-PLA2-IN-14
T79074
Lp-PLA2-IN-14 (Compound 19), an inhibitor of rhLp-PLA2, exhibits a potent inhibitory effect with a pIC50 value of 8.4. This compound is applicable in research pe...
Lp-PLA2-IN-15
T79075
Lp-PLA2-IN-15 (example 2) is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with potential application in Alzheimer's disease research [1].
Lp-PLA2-IN-16
T79076
Lp-PLA2-IN-16 (Example 1) is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with potential applications in Alzheimer's disease research [1].
nSMase2-IN-1
T79321
nSMase2-IN-1 is an orally active inhibitor of Neutral sphingomyelinase 2 (nSMase2) with a potent IC50 value of 0.13 ± 0.06 μM. It demonstrates metabolic stabilit...
FAAH/cPLA2α-IN-1
T82421
FAAH/cPLA2α-IN-1 is a compound that simultaneously inhibits both FAAH and cPLA2α, demonstrating potent activity with half-maximal inhibitory concentrations (IC50...
A4333
T83225
A4333, a biotinylated derivative of A3373, selectively inhibits Phospholipase D1 (PLD1) while sparing PLD2. It is noted for its significant role in antitumor act...
A3373
T83226
A3373 is a novel inhibitor targeting both Phospholipase D1 (PLD1) and Phospholipase D2 (PLD2), demonstrating half maximal inhibitory concentrations (IC50) of 325...
LCL521
T11835
LCL521 inhibits lysosomal acid sphingomyelinase (ASMase).LCL521 is an acid ceramidase (ACDase) inhibitor.
5α-Hydroxycostic acid
TN3139
5alpha-Hydroxycostic acid possesses anti-angiogenic ability by interfering the VEGF- and Ang2-related pathways, and it may be a good drug candidate.
ASM-IN-1
T74778
ASM-IN-1 is a potent, orally active inhibitor of acid sphingomyelinase (ASM) with an IC50 of 1.5 µM, demonstrating antiatherosclerotic and anti-inflammatory acti...
Desketoraloxifene
T9001
Desketoraloxifene is a selective estrogen receptor modulator, inhibiting mammalian PLD (PLD1 and PLD2).
Ikshusterol 3-O-glucoside
TN4247
Ikshusterol 3-O-glucoside has a potent snake-venom neutralizing capacity and it might be a potential molecule for the therapeutic treatment for snakebites.
ML299
T8968
ML299 (VU0463568) is a dual PLD1/2 inhibitor (PLD1 and PLD2, IC50 of 6 nM, 20 nM, respectively).
1 2 3 4 5
TargetMol